{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:46:36Z","timestamp":1767134796325,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd006097","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2007,1,24]],"date-time":"2007-01-24T00:00:00Z","timestamp":1169596800000}}],"reference-count":22,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006097.pub2","type":"journal-article","created":{"date-parts":[[2007,2,6]],"date-time":"2007-02-06T14:24:55Z","timestamp":1170771895000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Natalizumab for induction of remission in Crohn's disease"],"prefix":"10.1002","author":[{"given":"John K","family":"MacDonald","sequence":"first","affiliation":[{"name":"Robarts Research Institute; Robarts Clinical Trials; P.O. Box 5015 100 Perth Drive London Ontario Canada N6A 5K8"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John WD","family":"McDonald","sequence":"additional","affiliation":[{"name":"Robarts Research Institute; Robarts Clinical Trials; P.O. Box 5015 100 Perth Drive London Ontario Canada N6A 5K8"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,1,24]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD006097.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa020732","article-title":"Natalizumab for active Crohn's disease","volume":"348","author":"Ghosh","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1002\/14651858.CD006097.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/gast.2001.26260","article-title":"A randomized placebo-controlled trial of humanized monoclonal antibody to alpha4 integrin in active Crohn's disease","volume":"121","author":"Gordon","year":"2001","journal-title":"Gastroenterology"},{"issue":"18","key":"10.1002\/14651858.CD006097.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn's disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N Engl J Med"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD006097.pub2-BIB0004|cit4","first-page":"A108","article-title":"Natalizumab induces sustained response and remission with active Crohn's disease: results from the ENCORE trial","volume":"130","author":"Targan","year":"2006","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD006097.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMc055235","article-title":"Natalizumab and progressive multifocal leukoencephalopathy","volume":"353","author":"Adelman","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1002\/14651858.CD006097.pub2-BIB0006|cit6","article-title":"Assessment of study quality. Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]; Section 6","author":"Alderson","year":"2004","journal-title":"The Cochrane Library"},{"issue":"4","key":"10.1002\/14651858.CD006097.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1056\/NEJMe058122","article-title":"Progressive multifocal leukoencephalopathy and natalizumab--unforseen consequences","volume":"353","author":"Berger","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1002\/14651858.CD006097.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1600-6143.2005.00742.x","article-title":"Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction","volume":"5","author":"Brennan","year":"2005","journal-title":"Am J Transplant"},{"issue":"22","key":"10.1002\/14651858.CD006097.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJM198312013092204","article-title":"Bias in treatment assignment in controlled clinical trials","volume":"309","author":"Chalmers","year":"1983","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1002\/14651858.CD006097.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1053\/gast.1996.v111.pm8898653","article-title":"Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7","volume":"111","author":"Hesterberg","year":"1996","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD006097.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"4","key":"10.1002\/14651858.CD006097.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-Demasters","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1002\/14651858.CD006097.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1002\/14651858.CD006097.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"N Engl J Med"},{"issue":"9128","key":"10.1002\/14651858.CD006097.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD006097.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1172\/JCI116575","article-title":"Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody","volume":"92","author":"Podolsky","year":"1993","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1002\/14651858.CD006097.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1002\/14651858.CD006097.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1002\/14651858.CD006097.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD006097.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1212\/WNL.53.3.466","article-title":"The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group","volume":"53","author":"Tubridy","year":"1999","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006097.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease","volume":"353","author":"Assche","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1002\/14651858.CD006097.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","article-title":"Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy","volume":"354","author":"Yousry","year":"2006","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1002\/14651858.cd006097.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006097.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:54:56Z","timestamp":1628531696000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006097.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2007,1,24]]},"references-count":22,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006097.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,24]]}}}